Grace Therapeutics
GRCE
17 hedge funds and large institutions have $9.17M invested in Grace Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more capital invested
Capital invested by funds: $7.84M → $9.17M (+$1.33M)
13% more funds holding
Funds holding: 15 → 17 (+2)
8.74% more ownership
Funds ownership: 20.59% → 29.33% (+8.7%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.71M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.52M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$928K |
| 4 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$145K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$95.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$1.36M |
| 2 |
Renaissance Technologies
New York
|
-$2.5K |
| 3 |
GSWM
Golden State Wealth Management
Santa Ana,
California
|
-$116 |
| 4 |
Morgan Stanley
New York
|
-$107 |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$85 |
GRCE Hedge Fund Activity: Q1 2025 in Review
17 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2025, worth a combined $9.17M — up 17% from $7.84M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GRCE positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.71M. The largest seller was ADAR1 Capital Management, cutting an estimated $1.36M.
- 17 institutional investors held Grace Therapeutics (GRCE) as of Q1 2025, up from 15 in Q4 2024.
- Funds reported $9.17M of Grace Therapeutics stock for Q1 2025, up 17% quarter-over-quarter.
- 3 funds opened new Grace Therapeutics positions in Q1 2025 and 1 closed out, a net change of +2 holders.
- The largest Grace Therapeutics buyer in Q1 2025 was Nantahala Capital Management, an estimated $3.71M added.
- The largest Grace Therapeutics seller in Q1 2025 was ADAR1 Capital Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2025.